How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about ribociclib

Marketing authorisation indication

2.1

Ribociclib (Kisqali, Novartis) 'in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist'.

Price

2.3

The list prices of ribociclib 200-mg tablets are:

  • £983.33 per 21-pack

  • £1,966.67 per 42-pack

  • £2,950.00 per 63-pack
    (excluding VAT; BNF online, accessed March 2025).

2.4

The company has a simple patient access scheme. This makes ribociclib available to the NHS with a discount. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Novartis will be included here when guidance is published.